Figure 1

Treatment schedule. Patients received an imaging cycle with TF2 and ¹¹¹In-IMP288 to determine the pharmacokinetics and radiation dose to the red bone marrow and kidneys. A safe, cumulative ¹⁷⁷Lu-activity dose was estimated, and one-fourth of this amount was administered in the first therapy cycle.